%0 Journal Article
%T HER2阳性晚期乳腺癌一线治疗的共识和争议<br>Consensus and Controversy on First-Line Treatment of HER2 Positive Advanced Breast Cancer
%A 梅香萍
%A 胡悦
%A 姚静
%J Advances in Clinical Medicine
%P 161-166
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/acm.2024.1461758
%X 人表皮生长因子受体-2 (HER2)扩增是HER2阳性乳腺癌的侵袭性高、预后差的重要因素。抗HER2靶向药物的出现明显提高了患者的生存期，极大改善了预后。目前HER2阳性晚期乳腺癌一线治疗的标准治疗方案为曲妥珠单抗联合帕妥珠单抗和化疗，然而，仍有临床问题存在争议，包括HER2阳性晚期乳腺癌晚期一线选择帕妥珠单抗还是酪氨酸激酶抑制剂，既往接受曲妥珠单抗治疗患者该如何选择，HER2阳性脑转移患者靶向治疗的对比，激素受体阳性HER2阳性病人内分泌治疗和化疗该如何取舍，目前新的药物和联合治疗的进展。我们对此进行综述，以期为HER2阳性晚期乳腺癌的临床治疗提供参考。<br />
The amplification of human epidermal growth factor receptor-2 (HER2) is an important factor in the high invasiveness and poor prognosis of HER2 positive breast cancer. The emergence of anti-HER2 targeting drugs significantly increased the survival time of patients and greatly improved the prognosis. At present, the standard first-line treatment for HER2-positive advanced breast cancer is trastuzumab combined with patuzumab and chemotherapy. However, there are still some clinical issues in dispute, including the choice of first-line HER2-positive breast cancer with patuzumab or TKI, the optimal regimen for patients who have previously received trastuzumab, and the comparison of targeted therapy for patients with HER2-positive brain metastasis. How to choose between endocrine therapy and chemotherapy in hormone receptor positive HER2 positive patients? We review the progress of new drugs and combined therapy, in order to provide reference for the clinical treatment of HER2 positive advanced breast cancer.
%K HER2阳性，晚期乳腺癌，一线治疗<br>HER2 Positive
%K Advanced Breast Cancer
%K First Line Treatments
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=88868